[go: up one dir, main page]

UY34812A - Método para el tratamiento del cáncer de pulmón de células no pequeñas - Google Patents

Método para el tratamiento del cáncer de pulmón de células no pequeñas

Info

Publication number
UY34812A
UY34812A UY0001034812A UY34812A UY34812A UY 34812 A UY34812 A UY 34812A UY 0001034812 A UY0001034812 A UY 0001034812A UY 34812 A UY34812 A UY 34812A UY 34812 A UY34812 A UY 34812A
Authority
UY
Uruguay
Prior art keywords
treatment
lung cancer
small cells
cells
small
Prior art date
Application number
UY0001034812A
Other languages
English (en)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34812A publication Critical patent/UY34812A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos para el tratamiento de un paciente quien padece cáncer de pulmón d e células no pequeñas metastásico o avanzado, no resecable, cuyos métodos comprenden administrar al paciente quimioterapia que comprende una cantida d de docetaxel y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCT TCATCAT donde el oligonucleótido anti-clusterina tiene una columna vertebral fósforotioato a su través, tiene mitades de azúcar de los nucleótidos 1 -4 y 18-21 que portan modificaciones 2´-O-metoxietilo,los nucleótidos 5-17 que son 2´desoxinucleóti dos y 5-metilcitosinas en los nucleótidos 1, 4 y 19. La invención proporciona composiciones, combin aciones, paquetes y usos de los mismos
UY0001034812A 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas UY34812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
UY34812A true UY34812A (es) 2013-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034812A UY34812A (es) 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (es)
EP (1) EP2849761A1 (es)
JP (1) JP2015522542A (es)
KR (1) KR20150024843A (es)
CN (1) CN104684564A (es)
AR (1) AR091090A1 (es)
AU (1) AU2013262589A1 (es)
BR (1) BR112014028787A2 (es)
CA (1) CA2874092A1 (es)
EA (1) EA201492148A1 (es)
IL (1) IL235459A0 (es)
IN (1) IN2014DN10390A (es)
PH (1) PH12014502569A1 (es)
SG (1) SG11201407649RA (es)
TW (1) TW201402132A (es)
UY (1) UY34812A (es)
WO (1) WO2013173757A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144975A0 (en) 1999-02-26 2002-06-30 Univ British Columbia A composition containing an antisense oligonucleotide
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP3581105B1 (en) 2010-05-08 2022-08-31 The Regents of the University of California Apparatus for early detection of ulcers by scanning of subepidermal moisture
KR20140038388A (ko) 2011-03-15 2014-03-28 더 유니버시티 오브 브리티쉬 콜롬비아 전립선암의 치료를 위한 항-클러스테린 올리고뉴클레오타이드와 hsp90 저해제의 병용
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
CA3059988C (en) 2015-04-24 2023-03-07 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
MX2019004926A (es) 2017-02-03 2019-06-20 Bruin Biometrics Llc Medicion del edema.
ES3008659T3 (en) 2017-02-03 2025-03-24 Bbi Medical Innovations Llc Measurement of susceptibility to diabetic foot ulcers
CA3042093A1 (en) 2017-02-03 2018-08-09 Bruin Biometrics, Llc Measurement of tissue viability
EP3562392A4 (en) 2017-11-16 2021-06-09 Bruin Biometrics, LLC STRATEGIC TREATMENT OF SULSURES USING SUBEPIDERMAL MOISTURE VALUES
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
ES2984425T3 (es) 2018-02-09 2024-10-29 Bruin Biometrics Llc Detección de daños tisulares
US10950960B2 (en) 2018-10-11 2021-03-16 Bruin Biometrics, Llc Device with disposable element
WO2022169850A1 (en) 2021-02-03 2022-08-11 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
WO2009155381A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
SG194931A1 (en) * 2011-05-19 2013-12-30 Teva Pharma Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
US20130310440A1 (en) 2013-11-21
KR20150024843A (ko) 2015-03-09
WO2013173757A8 (en) 2015-04-30
AU2013262589A1 (en) 2015-01-22
JP2015522542A (ja) 2015-08-06
AR091090A1 (es) 2014-12-30
EA201492148A1 (ru) 2015-04-30
IL235459A0 (en) 2014-12-31
IN2014DN10390A (es) 2015-08-14
BR112014028787A2 (pt) 2017-06-27
CN104684564A (zh) 2015-06-03
PH12014502569A1 (en) 2015-01-21
TW201402132A (zh) 2014-01-16
CA2874092A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21
SG11201407649RA (en) 2014-12-30
EP2849761A1 (en) 2015-03-25

Similar Documents

Publication Publication Date Title
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
IL288181A (en) Cancer treatment methods
IL289300A (en) Combination therapy for treating cancer
IL272905A (en) Methods of treating pancreatic cancer
IL236336A0 (en) Methods of treating breast cancer with gemcitabine therapy
IL237791A0 (en) A method for treating cancer
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
PL3454346T3 (pl) APARAT DO CYKLOTRONOWEGO WYTWARZANIA TECHNETU-99m
LT2885010T (lt) Tautopatijos gydymo būdai
SG11201605585SA (en) Targeted therapy for small cell lung cancer
HUE048876T2 (hu) Rákos megbetegedések kezelése
BR112014032105A2 (pt) método para o tratamento de câncer
PL2739153T3 (pl) Leczenie raka sutka
EP2908843A4 (en) METHOD FOR TREATING CARCINOMA
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
EP2892536A4 (en) METHOD FOR TREATING LEUKEMIA
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
EP2971146A4 (en) METHOD FOR THE TREATMENT OF PANCREATIC CANCER
BR112014027219A2 (pt) método
UY34604A (es) Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación
EP2819706A4 (en) TARGETED TREATMENT OF ANAEROBIC CARCINOMA
EP3252171B8 (en) Methods of treating cancer
UY34277A (es) Metodo para la eliminación del naftaleno

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528